Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler

Colloids and Surfaces B: Biointerfaces

Volumn 79, Issue 2, 2010, Pages 345-356

  Kaialy, Waseem ^a,b   Momin, Mohammed N ^a   Ticehurst, Martyn D ^c   Murphy, John ^c   Nokhodchi, Ali ^a,d  

^a UNIVERSITY OF KENT   (United Kingdom)

^b DAMASCUS UNIVERSITY   (Syrian Arab Republic)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Deposition test; Dry powder inhaler; Elongation ratio; Engineered mannitol; Fine particle fraction; Non solvent precipitation technique; Solid state characterisation

Indexed keywords

CHARACTERISATION; DRY POWDER INHALER; ELONGATION RATIO; FINE PARTICLE FRACTION; FINE PARTICLE FRACTIONS; NON-SOLVENTS;

CONTROLLED DRUG DELIVERY; CRYSTALS; ELONGATION; ETHANOL; MORPHOLOGY; NEEDLES; PACKET NETWORKS; PRECIPITATION (CHEMICAL); RECRYSTALLIZATION (METALLURGY); SOLVENTS;

DRUG PRODUCTS;

ALCOHOL; MANNITOL; SALBUTAMOL SULFATE; SOLVENT; WATER; DRUG CARRIER; POWDER; SALBUTAMOL;

AEROSOL; AQUEOUS SOLUTION; ARTICLE; ATOMIC FORCE MICROSCOPY; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; COMPARATIVE STUDY; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRY POWDER; IN VITRO STUDY; INFRARED SPECTROSCOPY; INHALER; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SOLID STATE; X RAY DIFFRACTION; CHEMISTRY; DRUG EFFECTS; LUNG; NEBULIZER; POWDER; PROCEDURES; SURFACE PROPERTY;

ALBUTEROL; CALORIMETRY, DIFFERENTIAL SCANNING; CRYSTALLIZATION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; LUNG; MANNITOL; MICROSCOPY, ELECTRON, SCANNING; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES; X-RAY DIFFRACTION;

EID: 77953915537     PISSN: 09277765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2010.04.016     Document Type: Article

References (36)

1. Pilcer G. New Highly Effective Dry Powder Tobramycin Formulations for Inhalation in the Treatment of Cystic Fibrosis 2008, Universite libre de Bruxelles Institut de Pharmacie Laboratoire de Pharmacie Galénique et de Biopharmacie.
2. Timsina M., Martin G.P., Marriott C., Ganderton D., Yainneskis M. Int. J. Pharm. 1994, 101:1.
3. Rodri{dotless}óguez-Spong B., Price C.P., Jayasankar A., Matzger A.J., Rodri{dotless}óguez Hornedo N. Adv. Drug Deliv. Rev. 2004, 56:241.
4. Brittain H.G. Phys. Charact. Pharm. Solids 1995, 70.
5. Zeng X.M., Pandhal K.H., Martin G.P. Int. J. Pharm. 2000, 197:41.
6. Maa Y.F., Prestrelski S.J. Curr. Pharm. Biotechnol. 2000, 1:283.
7. Thompson P.J. Am. J. Respir. Crit. Care Med. 1998, 157:S199.
8. Chan H.K., Chew N.Y.K. Adv. Drug Deliv. Rev. 2003, 55:793.
9. Ganderton D., Kassem N.M. Adv. Pharm. Sci. 1992, 6:165.
10. Zeng X.M., Martin G.P., Marriott C., Pritchard J. J. Pharm. Sci. 2001, 90:1424.
11. Srichana T., Martin G.P., Marriott C. Int. J. Pharm. 1998, 167:13.
12. USP Pharmacopeia, Official Compendia of Standards, USP 26/NF 21 2003, United States Pharmacopeial Conventio, Inc., Rockville, MD, p. 2114.
13. Dhumal R.S., Biradar S.V., Paradkar A.R., York P. Int. J. Pharm. 2009, 368:129.
14. Pritchard J.N. J. Aerosol Med. 2001, 14:19.
15. Hemwimon S., Pavasan P., Shotipruk A. Sep. Purif. Technol. 2007, 54:44.
16. Burger A., Jan-Olav H., Hetz S., Rollinger J.M., Weissnicht A.A., Stottner H. J. Pharm. Sci. 2000, 89:457.
17. Campbell Roberts S.N., Williams A.C., Grimsey I.M., Booth S.W. J. Pharm. Biomed. Anal. 2002, 28:1149.
18. Yoshinari T., Forbes R.T., York P., Kawashima Y. Int. J. Pharm. 2002, 247:69.
19. Walter-Levy L. Acad. Sci. Paris Ser. C 1968, 267:1779.
20. Vippagunta S.R., Brittain H.G., Grant D.J.W. Adv. Drug Deliv. Rev. 2001, 48:3.
21. Hulse W.L., Forbes R.T., Bonner M.C., Getrost M. Int. J. Pharm. 2009, 382:67.
22. Debord B., Lefebvre C., Guyot-Hermann A.M., Hubert J., Bouche R., Cuyot J.C. Drug Dev. Ind. Pharm. 1987, 13:1533.
23. Jones F., Lee K. Microscope 1970, 18:279.
24. Larhrib H., Martin G.P., Marriott C., Prime D. Int. J. Pharm. 2003, 257:283.
25. Flament M., Leterme P., Gayot A. Int. J. Pharm. 2004, 275:201.
26. Byron P.R., Kelly E.L., Kontny M.J., Lovering E.G., Poochikian G.K., Sethi S. Pharm. Forum 1994, 20:7477.
27. Adams W.P., Christopher D., Lee D.S., Morgan B., Pan Z., Singh G.J.P., Tsong Y., Lyapustina S. AAPS Pharm. Sci. Technol. 2007, 8:32.
28. Swift D.L., Proctor D.F. Atmos. Environ. 1982, 16:2279.
29. Fults K.A., Miller I.F., Hickey A.J. Pharm. Dev. Technol. 1997, 2:67.
30. Podczeck F. Int. J. Pharm. 1998, 160:119.
31. Clay M.M., Pavia D., Clarke S.W. Br. Med. J. 1986, 41:364.
32. Rees P.J., Clark T.J., Moren F. Eur. J. Respir. Dis. Suppl. 1982, 119:738.
33. Zanen P., Go L.T., Lammers J.W. Br. Med. J. 1996, 51:977.
34. Zanen P., Go L.T., Lammers J.W.J. Int. J. Pharm. 1995, 114:111.
35. Zanen P., Go L.T., Lammers J.W.J. Int. J. Pharm. 1994, 107:211.
36. Kaialy W., Martin G.P., Ticehurst M.D., Momin M.N., Nokhodchi A. Int. J. Pharm. 2010, 392:178-188.